Brand’s largest brick-and-mortar expansion to date brings roadside emergency power off Amazon and onto Walmart shelves nationwide

SAN FRANCISCO, California, Aug. 4, 2026 /PRNewswire/ — GOOLOO, a global leader in portable power and roadside safety solutions, today announced the in-store launch of three of its best-selling jump starters — the GOOLOO A3X, GOOLOO G7X, and GOOLOO GE1500X — now available at approximately 4,000 Walmart stores across the United States. The rollout marks GOOLOO’s largest brick-and-mortar expansion to date, bringing the brand’s roadside emergency technology from online marketplaces directly to shoppers nationwide.

“Nearly half of the more than 32 million roadside assistance calls AAA receives each year involve dead batteries, flat tires, or lockouts. We wanted these three jump starters within arm’s reach of shoppers, not a shipping label away,” said Michael, General Manager at GOOLOO.

Until now, GOOLOO’s jump starters have been sold primarily through e-commerce channels. Their arrival at Walmart gives U.S. drivers same-day access to emergency power products, addressing a common frustration among customers who need battery assistance immediately rather than waiting on shipping.

The three products now available at Walmart include:

GOOLOO A3X 3000A Jump Starter with Air Compressor 

Designed as an all-in-one roadside solution, the A3X combines emergency jump-starting capability with a built-in tire inflator, helping drivers handle two of the most common roadside situations: dead batteries and low tire pressure.

Featuring automatic shut-off inflation, emergency lighting, USB power functionality, and GOOLOO’s SUPERSAFE™ protection system with multiple layers of battery safety protection, the A3X provides drivers with confidence and convenience in one compact device.

GOOLOO G7X 3000A Jump Starter 

The G7X introduces a new approach to everyday jump starter design by combining emergency starting capability with portable charging convenience.

Its integrated USB-C 45W fast-charging cable serves as both a built-in charging solution and a compact carry design feature, allowing users to charge smartphones, including the latest USB-C devices, and select laptops.

By increasing everyday usability beyond emergency situations, the G7X transforms the traditional jump starter from a product stored away for occasional emergencies into a practical portable power companion.

GOOLOO GE1500X 1500A Jump Starter

Designed for everyday drivers, the GE1500X delivers reliable emergency starting power with a compact and easy-to-use design.

Featuring emergency lighting, USB power functionality, and advanced safety protections, the GE1500X provides dependable roadside support for daily driving needs.

The GE1500X offers 1500A peak current for vehicles up to 6.0L gas or 4.0L diesel engines, a 400-lumen emergency flashlight with SOS mode, and UL 2743 / c-TUV-us certified safety protections.

All three jump starters are available now at Walmart stores nationwide and on Walmart.com, in addition to GOOLOO’s existing online retail channels.

About GOOLOO

GOOLOO is a leading global automotive roadside safety ecosystem brand specializing in high-performance lithium-ion portable jump starters, tire inflators, and multi-functional emergency tools. With its patented technologies SUPERSAFE®, JUMPCORE™ and TOOLCORE™, it has been serving millions of customers and drivers for over 12 years.

BUKIT MERTAJAM, Malaysia, Aug. 3, 2026 /PRNewswire/ — KPJ Healthcare Berhad (“KPJ Healthcare” or “the Group”) today launched its first Orthopaedic and Rheumatology Centre of Excellence (“CoE”) at KPJ Penang Specialist Hospital (“KPJ Penang”), marking the third CoE under the KPJ Health System (“KPJHS”). As Malaysia’s first private integrated academic health system, the Group continues to advance specialised musculoskeletal and joint care through the integration of Practice, Education, Research and Innovation.

Designed to support the management of complex conditions, the Orthopaedic and Rheumatology CoE integrates orthopaedic subspecialties, rheumatology and multidisciplinary expertise such as rehabilitation within a coordinated model of care. Bringing together consultations, diagnostic imaging, treatment rooms and advanced rehabilitation together on a single floor, the Centre provides a more seamless patient experience from diagnosis through rehabilitation and recovery. Comprehensive services include general orthopaedics, spine surgery, arthroplasty (joint replacement), arthroscopy and sports surgery, foot and ankle surgery, hand and microsurgery, paediatric orthopaedics, trauma and fracture management, rheumatology and pain services.

Its capabilities are further enhanced by AI-assisted robotic joint replacement surgery, computer-assisted navigation and minimally invasive surgical techniques, supporting greater surgical precision, improved mobility and faster functional recovery. Supporting these capabilities are tailored rehabilitation programmes, including post-spine surgery, post-sports injury and paediatric orthopaedic rehabilitation, supported by specialised technologies such as an anti-gravity treadmill.

YBhg. Datuk Syed Mohamed Syed Ibrahim, Chairman of the KPJHS Governing Council, Chairman of KPJ Healthcare University Sdn. Bhd. and President & Chief Executive of Johor Corporation (“JCorp”) said, “Our ambition for every Centre of Excellence in the KPJ Health System, including the one we launch today, is not that it should remain a Centre in perpetuity. Our ambition is for it to continue growing, strengthening its clinical, academic and research capabilities until, over time, it is elevated into an Institute: a destination in its clinical discipline, a generator of published evidence, a trainer of national and international leaders, and a partner sought after by industry, academia and governments. World-class in the fullest meaning of that phrase.”

The Orthopaedic and Rheumatology CoE builds on the establishment of the Heart & Lung Centre of Excellence at Johor Specialist Hospital and the Neuroscience & Stroke Centre of Excellence at Damansara Specialist Hospital 2, reinforcing KPJ Healthcare’s long-term strategy to establish 15 Centres of Excellence nationwide by 2030 under the KPJHS. Through its integrated hub model anchored by KPJ Penang Specialist Hospital together with KPJ Selangor Specialist Hospital, the Centre enables shared expertise, common clinical standards, coordinated research and multidisciplinary collaboration across the KPJ Health System, demonstrating how specialised care can be delivered through one integrated academic health system. This integrated approach also provides the platform to accelerate the convergence of artificial intelligence, genomics and value-based care in shaping the future of specialised healthcare delivery.

KPJ Penang is a 270-bed tertiary hospital supported by more than 50 resident consultants across over 20 medical specialties. The establishment of the Orthopaedic and Rheumatology CoE further strengthens the hospital’s role within the KPJHS. Through the Centre, patients benefit from greater access to advanced orthopaedic treatments that have demonstrated improved patient-reported outcomes and shorter hospital stays. Complementing these capabilities, KPJ Penang is also the first in the Northern Region to provide advanced wound care management and, in collaboration with KPJ Healthcare University, is developing Malaysia’s first AI-assisted remote telewound care programme.

ENDS

About KPJ Healthcare Berhad 

KPJ Healthcare operates 30 hospitals across Malaysia and four Ambulatory Care Centres, serving 3.3 million patients annually with 1,491 medical consultants. Nineteen hospitals are accredited by MSQH and four by JCI. As Malaysia’s first private healthcare provider to establish an Academic Health System, KPJHS integrates practice, education and research & innovation to drive clinical excellence and patient experience. Beyond hospitals, KPJ Healthcare operates Klinik Waqaf An-Nur (KWAN) clinics, dialysis centres and mobile clinics nationwide, and offers more than 40 academic programmes at KPJ Healthcare University (KPJU). KPJ Healthcare has been a constituent of the Bursa Malaysia FTSE4Good Index since 2016.

HUALIEN, Aug. 3, 2026 /PRNewswire/ — For the first time ever, the Hualien County Government has launched a crossover collaboration with the globally ultra-popular IP, ONE PIECE! The massive 15-meter-long Thousand Sunny has officially set sail for Liyu Lake in Shoufeng Township, becoming the biggest highlight of the event. Making a simultaneous debut are six all-new classic character installations, which are placed in combination with Hualien’s diverse local features:

• Usopp at Hualien Railway Station, echoing the imagery of a new adventure setting off.
• Zoro at the century-old General’s House (Chiang Chün Fu). Fusing Japanese architecture with cultural heritage, the site echoes the perseverance and conviction represented by Zoro.
• Luffy at the bustling Dongdamen Night Market. Gathering Hualien’s local delicacies, it is a crucial hub for travelers to experience local flavors—something the food-loving Luffy could never miss.
• Sanji at Sunrise Square. Boasting views of Hualien Fishing Harbor, it presents a rich marine culture and fresh ingredients, echoing Sanji’s vitality and passion.
• Nami at Zhikaxuan Forest Park. Surrounded by lush greenery and ecological landscapes, the park provides a space for families to relax and experience nature.
• Chopper at the event’s main venue, Liyu Lake in Shoufeng Township. Famous for its stunning lake and mountain scenery, the area offers a tourism atmosphere that is both for sightseeing and therapeutic healing, perfectly echoing Chopper’s character traits!

The Hualien County Government stated that the event will run until August 20. In addition to a stamp rally mission, the nighttime will feature spectacular water and light shows, starry sky fireworks displays, and world-class fire dance performances!

-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight across two pivotal trials in the U.S., Europe, and Canada.

-Positive preclinical data in non-human primates announced for first-in-class once-daily oral small molecule GLP-1/GIP/amylin fixed-dose combination.

-Industry leading one-pill once-daily oral small molecule portfolio for obesity and other metabolic diseases: five programs spanning GLP-1, GIP, and amylin targets, alone and in fixed-dose combinations.

-Sufficient cash on hand to support operations into 2029, beyond the expected submission of a New Drug Application (NDA) in the U.S. by the end of 2028 and a Marketing Authorisation Application (MAA) in Europe in early 2029 for ASC30.

HONG KONG, Aug. 3, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces once-daily oral small molecule GLP-1 (ASC30) has received Phase III clearance from the U.S. Food and Drug Administration (FDA). ASC30 is the primary pillar of Ascletis’ oral small molecule obesity portfolio. The Company has initiated a global Phase III program for ASC30 chronic weight management indication consisting of two pivotal global Phase III, multicenter, randomized, double-blind, placebo-controlled trials (AURORA-1 NCT07743463 and AURORA-2 NCT07743450) in a total of approximately 4,600 participants with obesity or overweight in the U.S., Europe, and Canada. The two pivotal studies will investigate the long-term efficacy, safety, and tolerability of three maintenance doses (20 mg, 40 mg and 60 mg) of once-daily oral ASC30 compared with placebo in participants with obesity or overweight without type 2 diabetes (AURORA-1) and in participants with obesity or overweight with type 2 diabetes (AURORA-2). The treatment duration of both AURORA-1 and AURORA-2 are 72 weeks, with titrations of 12 weeks, 16 weeks and 20 weeks for 20 mg, 40 mg and 60 mg maintenance dose cohorts, respectively. The Company expects to announce topline data from the ASC30 Phase III program in the third quarter of 2028, with a U.S. FDA New Drug Application (NDA) filing expected by the end of 2028 and a European Medicines Agency (EMA) Marketing Authorisation Application (MAA) filing expected in early 2029. If approved by the respective regulatory authorities in the U.S. and Europe, this will make ASC30 potentially the second oral small molecule GLP-1 approved in the U.S. and Europe after orforglipron. The Company has sufficient cash on hand to support operations into 2029, beyond the expected submission of an NDA and an MAA for ASC30.

Ascletis also announces positive data for its first-in-class once-daily oral small molecule GLP-1/GIP/amylin triple agonist fixed-dose combination (FDC). The addition of this triple agonist FDC gives Ascletis a highly comprehensive and advanced oral small molecule portfolio for the treatment of obesity and other metabolic diseases (Table 1). The portfolio includes a best-in-class Phase III once-daily oral small molecule GLP-1, a first-in-class once-daily oral small molecule GLP-1/GIP dual agonist FDC (the first tirzepatide-like oral small molecule combination), a first-in-class once-daily oral small molecule GLP-1/GIP/amylin triple agonist FDC (the first oral tirzepatide+eloralintide-like small molecule combination), and a first-in-class once-daily oral small molecule eloralintide-like selective amylin receptor agonist (SARA). This comprehensive portfolio places Ascletis in a unique competitive position to significantly expand the population that can be treated with oral agents.

Table 1. Ascletis Once-Daily Oral Small Molecule Portfolio

Notes: FDC: fixed-dose combination; SARA: selective amylin receptor agonist.

Oral Small Molecule Triple Agonist Combination (GLP-1/GIP/Amylin)

Ascletis’ first-in-class once-daily oral small molecule triple agonist FDC targeting GLP-1, GIP, and amylin (SARA) (ASC30_48_39FDC) demonstrated a GIPR agonist (ASC48) dose-dependent, statistically significant body weight reduction of up to 15.2% in non-human primates (NHPs) after seven-day treatment. This represents an up to 120% greater relative body weight reduction compared to oral dual agonist FDC targeting GLP-1R and amylin receptor (SARA) (ASC30_39FDC) (Table 2). The data suggest that GIP component (ASC48) is critical to ASC30_48_39FDC triple agonist. ASC30_48_39FDC is the oral small molecule triple agonist equivalent to injectable triple agonist peptides like tirzepatide+eloralintide which demonstrated a 29% reduction in body weight in humans at week 32 in a recently disclosed study ^[1].

Table 2. Once-Daily Oral Administration of ASC30_48_39FDC for Seven Consecutive Days in Non-Human Primates (NHPs)

Notes: FDC: fixed-dose combination; SARA: selective amylin receptor agonist; PO: oral administration; QD: once daily.

Oral Small Molecule Eloralintide-like SARA

Ascletis’ first-in-class once-daily oral small molecule eloralintide-like SARA (ASC39) is the second pillar of Ascletis oral small molecule obesity portfolio. ASC39 demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models (Press Release). ASC39 was 40-fold more selective for human amylin 1 receptor (hAMY1R) over human calcitonin receptor (hCTR), which is comparable to the 60-fold greater selectivity of eloralintide in the same preclinical model. Once-daily oral administration of 5 mg/kg ASC39 for six consecutive days in the diet-induced obese rats produced a weight loss of 6.0%, similar to eloralintide at 5.0% (Table 3). ASC30_39FDC, a GLP-1/amylin dual agonist FDC, is expected to be the first FDC of this type to enter the clinic in the fourth quarter of 2026.

Table 3. Once-Daily Oral Administration of ASC39 for Six Consecutive Days Compared to Eloralintide SQ in Obese Rats

Notes: Obese rats: diet-induced obese rats; SQ: subcutaneous; Q3D: once every 3 days; PO: oral administration; QD: once daily.

Oral Small Molecule Dual Agonist Combination (GLP-1/GIP)

Ascletis’ first-in-class once-daily oral dual FDC targeting GLP-1R and GIPR (ASC30_48FDC) demonstrated a 10.5% body weight reduction in non-human primates after eight-day treatment. This represents a 52% greater relative body weight reduction compared to ASC30 monotherapy (Press Release). ASC48, a first-in-class oral small molecule GIPR agonist, in a head-to-head in vitro study versus tirzepatide, demonstrated an EC₅₀ of 1 pM in the hGIPR cyclic adenosine monophosphate (cAMP) activation assay, exhibiting greater potency than tirzepatide (EC₅₀ = 3 pM). ASC30_48FDC represents the oral small molecule dual agonist equivalent to injectable dual agonist peptides like tirzepatide. Tirzepatide demonstrated up to a 20.9% reduction in body weight in humans as reported in the tirzepatide package insert^[2].

Table 4. Once-Daily Oral Administration of ASC30_48FDC for Eight Consecutive Days in Non-Human Primates (NHPs)

Notes: FDC: fixed-dose combination; PO: oral administration; QD: once daily.

“Following recent positive end-of-Phase II feedback received from the FDA for ASC30, we are excited to have initiated the global Phase III program of ASC30, the primary pillar of our one-pill once-daily oral small molecule obesity portfolio.” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. “ASC30 (GLP-1), ASC48 (GIP) and ASC39 (amylin SARA) are small molecules with different physical-chemical properties. We have overcome multiple challenges during the development of fixed-dose combinations of these molecules. The new data for our first-in-class oral small molecule triple agonist fixed-dose combination (GLP-1/GIP/amylin) reinforces our industry-leading, comprehensive and differentiated portfolio of one-pill once-daily oral small molecules for the treatment of obesity and other metabolic diseases.”

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes; ASC30_48 FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC48 (GIPR agonist), ASC30_48_39 FDC, a once-daily oral small molecule triple agonist, a fixed dose combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective amylin receptor agonist (SARA) once-daily small molecule, ASC30_39 FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC39 (amylin receptor agonist (SARA)), ASC36, an amylin peptide, designed to be administered once monthly to once quarterly subcutaneously and once daily orally, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35 FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered once monthly subcutaneously and once daily orally, and ASC36_37 FDC, a once-monthly subcutaneous quadruple peptide agonist, a fixed dose combination of ASC36 (amylin receptor agonist) and ASC37 (GLP-1R/GIPR/GCGR agonist), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com. 

Contact:
Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com 

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)
pr@ascletis.com 
ir@ascletis.com 

SEOUL, South Korea, Aug. 3, 2026 /PRNewswire/ — WATERBOMB SEOUL 2026 successfully concluded an unforgettable three-day celebration of music, entertainment and immersive fan experiences, bringing together tens of thousands of fans from Korea and around the world for one of Asia’s most anticipated summer festivals. Held at the KINTEX Outdoor Global Stage in Goyang, the event showcased the unique combination of live music and signature water-themed attractions that have made Waterbomb a global cultural phenomenon.

Fans experienced a diverse lineup of some of the biggest names in K-pop, hip-hop and electronic dance music with performances by global and regional stars including Jay Park, ZICO, KARINA, Taemin, Sunmi, and Shownu & Hyungwon of MONSTA X, among others.

Widely regarded as Korea’s premier water-themed music festival, Waterbomb once again delivered its signature blend of music, energy and audience participation. Beyond the performances, attendees took part in large-scale water battles and immersive interactive experiences that have become synonymous with the festival. Its unique format continues to distinguish it from other music events, creating an environment where audiences are participants rather than simply spectators.

The Seoul 2026 edition also marked a significant milestone for CSTS Enterprises and its PremierX brand, whose involvement reflects CSTS Group’s growing commitment to experiential live entertainment. Earlier this year, CSTS announced its strategic collaboration with MADEONE Corp., owner and operator of Waterbomb, to support continued development of the festival in Seoul and around its international expansion.

Through the partnership, CSTS and PremierX contributed their expertise in hospitality, entertainment strategy, audience engagement and brand development, helping reinforce Waterbomb’s position as one of the most influential festival properties from Asia. The successful execution of Waterbomb Seoul 2026 further demonstrates the strength of the partnership and the growing international appeal of the Waterbomb brand.

“Waterbomb is much more than a music festival. It is a global lifestyle and cultural platform that connects audiences through unforgettable experiences,” said Winnie Chan, General Manager, CSTS Integrated Marketing. “The success of Waterbomb Seoul 2026 highlights the power of collaboration between CSTS, PremierX and MADEONE, and reinforces our shared vision of bringing this iconic entertainment experience to audiences around the world.”

As the final water cannons fired and performances concluded, Waterbomb Seoul 2026 closed another landmark chapter in the festival’s history, setting the stage for continued international growth. Building on this momentum, CSTS and PremierX look forward to supporting the next phase of Waterbomb’s expansion, bringing the festival’s unique blend of music, community and immersive entertainment to new audiences across Asia and beyond.

About WATERBOMB

WATERBOMB is South Korea’s globally recognized water-themed music festival, combining performances from leading K-pop, hip-hop and EDM artists with large-scale interactive water experiences. Since its launch in 2015, the festival has expanded beyond Korea to become one of Asia’s most recognizable live entertainment brands.

About CSTS Enterprises

CSTS Enterprises is an integrated media, entertainment, sports, and travel technology group. The company develops and partners with intellectual properties and brands to deliver compelling experiences that connect with local and regional audiences across the world. In addition to its own initiatives, including Generation C and PremierX, it collaborates with international IPs such as the FIFA World Cup, Formula 1, and Waterbomb.

CSTS integrates experiential marketing, tourism, data, and technology to deliver connected audience experiences. The company engages consumers across physical events and digital channels, working with clients to execute at scale across markets, turning complex activations into co-ordinated, measurable outcomes.

About MADEONE Corp.

MADEONE Corp. is a Seoul-based creative production house and entertainment agency specializing in the development and execution of leading festival experiences. Guided by the philosophy, “If our hearts don’t beat, we cannot thrill anyone,” MADEONE has redefined the music festival landscape through its flagship brand, WATERBOMB®, integrating music, performance, and audience participation into a new entertainment paradigm. In addition to festival production, the company provides theatrical services and manages talent in the arts and entertainment. MADEONE continues to expand its global footprint through international editions of its high-energy events.